Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results from the informCLL ™ Registry

informCLL is the first US-based registry of patients with CLL that initiated enrollment after approval of novel-targeted agents. Prognostic/predictive testing rates and CLL treatment selection, with availability of novel agents, in clinical practice has not been previously investigated. Results from this interim analysis demonstrate that prognostic/predictive testing was infrequently used to guide treatment selection, potentially inhibiting beneficial outcomes for patients.

Source: Clinical Lymphoma, Myeloma and Leukemia - October 20, 2019 Category: Hematology Authors: Anthony R. Mato, Jacqueline C. Barrientos, Nilanjan Ghosh, John M. Pagel, Danielle M. Brander, Meghan Gutierrez, Karen Kadish, Brian Tomlinson, Reethi Iyengar, David Ipe, Sandhya Upasani, Carlos I. Amaya-Chanaga, Murali Sundaram, Jennifer Han, Nick Giafis Tags: Original Study Source Type: research